JANUS HENDERSON GROUP PLC - 02 Jul 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role: 10%+ Owner
Signature: /s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Issuer symbol: ORKA
Transactions as of: 02 Jul 2024
Net transactions value: +$1,427,345
Form type: 4
Filing time: 12 Jul 2024, 19:38:10 UTC
Next filing: 26 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABIO	Common Stock	Purchase	$589,565	+166,042	+11%	$3.55	1,648,577	03 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$80,015	+23,326	+1.4%	$3.43	1,671,903	05 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$17,050	+5,000	+0.3%	$3.41	1,676,903	05 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$101,974	+29,892	+1.8%	$3.41	1,706,795	08 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$62,216	+17,600	+1%	$3.54	1,724,395	08 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$58,091	+16,917	+0.98%	$3.43	1,741,312	09 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$116,067	+33,500	+1.9%	$3.46	1,774,812	10 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$76,062	+21,963	+1.2%	$3.46	1,796,775	10 Jul 2024	By Fund	F1
transaction	ABIO	Common Stock	Purchase	$326,304	+94,537	+5.3%	$3.45	1,891,312	11 Jul 2024	By Fund	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Content

The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.